Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTT | P42858 | 1/20 | 0.57 |
| ▸ | CACNA2D1 | P54289 | 5/20 | 0.57 |
| ▸ | CACNA1B | Q00975 | 5/20 | 0.57 |
| ▸ | CACNB1 | Q02641 | 5/20 | 0.57 |
| ▸ | HRH3 | Q9Y5N1 | 4/20 | 0.47 |
| ▸ | UTS2R | Q9UKP6 | 3/20 | 0.47 |
| ▸ | CACNA1C | Q13936 | 4/20 | 0.46 |
| ▸ | PRCP | P42785 | 1/20 | 0.46 |
| ▸ | MEN1 | O00255 | 1/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.44 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.44 |
| ▸ | CNR1 | P21554 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3396526 | 0.99 | HTT (0.56) | HTTCACNA2D1CACNA1BCACNB1HRH3 | |
| SCHEMBL3393189 | 0.89 | HTT (0.54) | HTTCACNA2D1CACNA1BCACNB1KMT2A | |
| SCHEMBL3392834 | 0.87 | HTT (0.57) | HTTCACNA2D1CACNA1BCACNB1CACNA1C | |
| SCHEMBL3395377 | 0.87 | HTT (0.57) | HTTCACNA2D1CACNA1BCACNB1HRH3 | |
| SCHEMBL3396198 | 0.86 | HTT (0.56) | HTTCACNA2D1CACNA1BCACNB1HRH3 | |
| SCHEMBL3391260 | 0.86 | HTT (0.56) | HTTCACNA2D1CACNA1BCACNB1HRH3 | |
| SCHEMBL3391284 | 0.85 | HTT (0.53) | HTTCACNA2D1CACNA1BCACNB1HRH3 | |
| SCHEMBL3432018 | 0.81 | HTT (0.80) | HTTCACNA2D1CACNA1BCACNB1HRH3 | |
| SCHEMBL3955152 | 0.80 | CCR2 (0.47) | HTTCACNA2D1CACNA1BCACNB1PRCP | |
| SCHEMBL3391930 | 0.78 | HTT (0.56) | HTTCACNA2D1CACNA1BCACNB1HRH3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1784401-A4 | UREA DERIVATIVES AS CALCIUM CHANNEL BLOCKERS | NEUROMED PHARMACEUTICALS LTD (CA) | 2009-07-15 | — | — | EP | claimed |
| EP-1784401-A1 | UREA DERIVATIVES AS CALCIUM CHANNEL BLOCKERS | Neuromed Pharmaceuticals, Ltd. (CA) | 2007-05-16 | — | — | EP | claimed |
| US-20060063775-A1 | Urea derivatives as calcium channel blockers | NEUROMED TECHNOLOGIES INC. | 2006-03-23 | — | — | US | claimed |
| WO-2006024160-A1 | UREA DERIVATIVES AS CALCIUM CHANNEL BLOCKERS | NEUROMED PHARMACEUTICALS LTD. (CA) | 2006-03-09 | — | — | WO | claimed |
| US-7659395-B2 | Urea derivatives as calcium channel blockers | NEUROMED PHARMACEUTICALS LTD. (CA) | 2010-02-09 | — | — | US | disclosed |
| US-7659395-B2 | Urea derivatives as calcium channel blockers | NEUROMED PHARMACEUTICALS LTD. (CA) | 2010-02-09 | — | — | US | disclosed |
| US-7659395-B2 | Urea derivatives as calcium channel blockers | NEUROMED PHARMACEUTICALS LTD. (CA) | 2010-02-09 | — | — | US | disclosed |
| US-7649092-B2 | Urea derivatives as calcium channel blockers | NEUROMED PHARMACEUTICALS LTD. (CA) | 2010-01-19 | — | — | US | disclosed |
| US-7649092-B2 | Urea derivatives as calcium channel blockers | NEUROMED PHARMACEUTICALS LTD. (CA) | 2010-01-19 | — | — | US | disclosed |
| US-7649092-B2 | Urea derivatives as calcium channel blockers | NEUROMED PHARMACEUTICALS LTD. (CA) | 2010-01-19 | — | — | US | disclosed |
| US-20080221117-A1 | UREA DERIVATIVES AS CALCIUM CHANNEL BLOCKERS | ZALICUS PHARMACEUTICALS LTD. (CA) | 2008-09-11 | — | — | US | disclosed |
| US-20080221117-A1 | UREA DERIVATIVES AS CALCIUM CHANNEL BLOCKERS | ZALICUS PHARMACEUTICALS LTD. (CA) | 2008-09-11 | — | — | US | disclosed |
| US-20080221117-A1 | UREA DERIVATIVES AS CALCIUM CHANNEL BLOCKERS | ZALICUS PHARMACEUTICALS LTD. (CA) | 2008-09-11 | — | — | US | disclosed |
| US-20080207633-A1 | UREA DERIVATIVES AS CALCIUM CHANNEL BLOCKERS | ZALICUS PHARMACEUTICALS LTD. (CA) | 2008-08-28 | — | — | US | disclosed |
| US-20080207633-A1 | UREA DERIVATIVES AS CALCIUM CHANNEL BLOCKERS | ZALICUS PHARMACEUTICALS LTD. (CA) | 2008-08-28 | — | — | US | disclosed |
| US-20080207633-A1 | UREA DERIVATIVES AS CALCIUM CHANNEL BLOCKERS | ZALICUS PHARMACEUTICALS LTD. (CA) | 2008-08-28 | — | — | US | disclosed |
| US-7378420-B2 | Urea derivatives as calcium channel blockers | NEUROMED PHARMACEUTICALS LTD. (CA) | 2008-05-27 | — | — | US | disclosed |
| US-7378420-B2 | Urea derivatives as calcium channel blockers | NEUROMED PHARMACEUTICALS LTD. (CA) | 2008-05-27 | — | — | US | disclosed |
| US-7378420-B2 | Urea derivatives as calcium channel blockers | NEUROMED PHARMACEUTICALS LTD. (CA) | 2008-05-27 | — | — | US | disclosed |
| US-20060063775-A1 | Urea derivatives as calcium channel blockers | NEUROMED TECHNOLOGIES INC. | 2006-03-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080207633-A1 | UREA DERIVATIVES AS CALCIUM CHANNEL BLOCKERS | ORAI1, ATP2A1, CACNA1B | HTT 1333/4885CACNA2D1 26/4885CACNA1B 3/4885 |
| US-20060063775-A1 | Urea derivatives as calcium channel blockers | ORAI1, ATP2A1, CACNA1B | HTT 1333/4885CACNA2D1 26/4885CACNA1B 3/4885 |
| US-20080221117-A1 | UREA DERIVATIVES AS CALCIUM CHANNEL BLOCKERS | ORAI1, ATP2A1, CACNA1B | HTT 1333/4885CACNA2D1 26/4885CACNA1B 3/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.